<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=The_Back_Remedies_For_Suplatast_tosilate</id>
		<title>The Back Remedies For Suplatast tosilate - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=The_Back_Remedies_For_Suplatast_tosilate"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=The_Back_Remedies_For_Suplatast_tosilate&amp;action=history"/>
		<updated>2026-06-17T17:49:55Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=The_Back_Remedies_For_Suplatast_tosilate&amp;diff=191811&amp;oldid=prev</id>
		<title>Bronzeedge83: Створена сторінка: 0%; p?[https://en.wikipedia.org/wiki/Suplatast_tosilate Suplatast tosilate] discharge were associated with bacterial SBO (p?��0.03), whereas sinonasal pain,...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=The_Back_Remedies_For_Suplatast_tosilate&amp;diff=191811&amp;oldid=prev"/>
				<updated>2017-06-20T12:27:35Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: 0%; p?[https://en.wikipedia.org/wiki/Suplatast_tosilate Suplatast tosilate] discharge were associated with bacterial SBO (p?��0.03), whereas sinonasal pain,...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;0%; p?[https://en.wikipedia.org/wiki/Suplatast_tosilate Suplatast tosilate] discharge were associated with bacterial SBO (p?��0.03), whereas sinonasal pain, facial or periorbital swelling and nasal stuffiness/discharge were more frequent in fungal SBO (p?��0.03). No significant differences in the frequency or magnitude of fever, or in the proportion of cranial [http://www.selleckchem.com/products/blu9931.html BLU9931 supplier] nerve deficits, were identified (Table?1). Overall, bacterial SBO was more likely than fungal SBO to have arisen from an otogenic focus of infection (80% vs. 18.2%; p?[http://www.selleckchem.com/products/ve-822.html Selleckchem VE822] therapy was 28?weeks. The median length of hospital stay for 19 patients was 3?weeks (bacterial SBO, 2.6?weeks; fungal SBO, 5?weeks; p: not significant). Six-month survival was 77% (14/18 patients); three patients with bacterial SBO were lost to follow-up. Four deaths occurred, all in patients with fungal SBO (median time from diagnosis to death: 8?weeks; range 2�C18?weeks). The cause of death in all cases was progressive fungal disease; secondary haemorrhage from mycotic aneurysms [internal carotid artery (n?=?1), superior cerebellar artery (n?=?1)] was contributory in two cases. Cranial nerve abnormalities persisted in all patients. The median time from symptom onset to initiation of therapy was 5?weeks (range 1�C13 weeks) in those who died compared to 11?weeks in survivors (range 2�C53?weeks; p: NS). Immunosuppression was the only factor associated with decreased survival by univariate analysis (40% vs.&lt;/div&gt;</summary>
		<author><name>Bronzeedge83</name></author>	</entry>

	</feed>